[go: up one dir, main page]

TR200605472T1 - AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ - Google Patents

AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@

Info

Publication number
TR200605472T1
TR200605472T1 TR2006/05472T TR200605472T TR200605472T1 TR 200605472 T1 TR200605472 T1 TR 200605472T1 TR 2006/05472 T TR2006/05472 T TR 2006/05472T TR 200605472 T TR200605472 T TR 200605472T TR 200605472 T1 TR200605472 T1 TR 200605472T1
Authority
TR
Turkey
Prior art keywords
receptors
treatment
receptor
increased
diseases caused
Prior art date
Application number
TR2006/05472T
Other languages
English (en)
Inventor
Rosemary Bullock Gillian
Maria Ganter Sabina
De Gasparo Marc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200605472(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200605472T1 publication Critical patent/TR200605472T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Buluş, sub-epitelial alandaki AT1 reseptörlerinin artışı veya epiteliadaki AT2 reseptörlerinin artışının neden olduğu hastalıkların ya da durumların tedavisi için farmasötik bir preparasyon üretmek amacıyla sırasıyla bir AT1 reseptör antagonistinin ya da bir AT2 reseptör modulatörünün ya da onun farmasötik olarak uygun bir tuzunun kullanımı ile ilgilidir.
TR2006/05472T 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ TR200605472T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98811257 1998-12-23
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors

Publications (1)

Publication Number Publication Date
TR200605472T1 true TR200605472T1 (tr) 2007-02-21

Family

ID=26152118

Family Applications (7)

Application Number Title Priority Date Filing Date
TR2002/00764T TR200200764T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
TR2008/05275T TR200805275T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2008/05740T TR200805740T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2001/01784T TR200101784T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı.
TR2008/05741T TR200805741T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@
TR2006/05472T TR200605472T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2006/05471T TR200605471T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@

Family Applications Before (5)

Application Number Title Priority Date Filing Date
TR2002/00764T TR200200764T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı
TR2008/05275T TR200805275T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2008/05740T TR200805740T1 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
TR2001/01784T TR200101784T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı.
TR2008/05741T TR200805741T2 (tr) 1998-12-23 1999-12-22 At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2006/05471T TR200605471T2 (tr) 1998-12-23 1999-12-22 AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@

Country Status (26)

Country Link
EP (3) EP2298298A3 (tr)
JP (2) JP2002533390A (tr)
KR (1) KR100646716B1 (tr)
CN (2) CN1304000C (tr)
AT (2) ATE524176T1 (tr)
AU (4) AU3043000A (tr)
BR (1) BR9916576A (tr)
CA (2) CA2351357A1 (tr)
CY (2) CY1106581T1 (tr)
CZ (2) CZ297795B6 (tr)
DE (1) DE69935249T2 (tr)
DK (2) DK1588706T3 (tr)
ES (2) ES2373556T3 (tr)
HK (1) HK1038888B (tr)
HU (1) HUP0104780A3 (tr)
ID (1) ID29856A (tr)
IL (5) IL143233A0 (tr)
NO (2) NO328775B1 (tr)
NZ (3) NZ587909A (tr)
PL (1) PL199100B1 (tr)
PT (2) PT1588706E (tr)
RU (3) RU2271809C2 (tr)
SI (2) SI1588706T1 (tr)
SK (1) SK9132001A3 (tr)
TR (7) TR200200764T2 (tr)
WO (1) WO2000038676A1 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20024180A3 (cs) * 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
JPWO2002083127A1 (ja) * 2001-04-09 2004-09-30 宮田　敏男 蛋白修飾物生成抑制組成物
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SK50472005A3 (sk) * 2003-11-03 2005-09-08 Zentiva, A. S. Tableta s obsahom valsartanu vyrobená priamym tabletovaním
ES2397552T3 (es) 2004-12-24 2013-03-07 Krka Composición farmacéutica sólida que comprende valsartán
PT1830869E (pt) * 2004-12-24 2013-08-22 Spinifex Pharm Pty Ltd Método de tratamento ou profilaxia
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110027358A1 (en) * 2007-03-29 2011-02-03 Rajesh Kshirsagar Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
AU2008311053B2 (en) 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan
FI3067043T3 (fi) * 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
WO2009092052A2 (en) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Methods and compositions for treating polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
US20220257698A1 (en) 2019-08-02 2022-08-18 Lanthiopep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) * 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
DE69033469T2 (de) 1989-06-14 2000-09-07 Smithkline Beecham Corp., Philadelphia Imidazoalkensäure
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
PH30484A (en) * 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
EP0551432A1 (en) * 1990-10-02 1993-07-21 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
WO1993020816A1 (en) 1992-04-13 1993-10-28 Zeneca Limited Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NZ258889A (en) 1992-12-11 1997-02-24 Ciba Geigy Ag 3-alkylamino-1,5-benzoxazepin- (and benzothiazepin-) 4-one derivatives and pharmaceutical compositions
WO1994013642A1 (de) 1992-12-11 1994-06-23 Ciba-Geigy Ag Substituierte benzazepinone
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995024901A1 (en) * 1994-03-17 1995-09-21 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
EP0853477B1 (en) 1995-10-06 2002-10-09 Novartis AG At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU2316997A (en) 1996-02-27 1997-09-16 David H Thompson Liposomal delivery system
US6174910B1 (en) 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
PT2322174E (pt) 1998-07-10 2015-10-27 Novartis Pharma Gmbh Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos
HUP0105199A3 (en) * 1999-01-26 2004-11-29 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
CZ20024180A3 (cs) * 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan
WO2005039637A2 (en) 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
EP2298298A3 (en) 2011-05-11
WO2000038676A1 (en) 2000-07-06
KR100646716B1 (ko) 2006-11-17
AU2009220022B2 (en) 2011-11-03
AU2006203077B2 (en) 2009-10-08
EP1588706B1 (en) 2011-09-14
AU2003266433B2 (en) 2006-08-10
ATE354364T1 (de) 2007-03-15
CN1304000C (zh) 2007-03-14
IL179015A0 (en) 2007-03-08
JP2010090169A (ja) 2010-04-22
EP1588706A3 (en) 2005-12-07
HUP0104780A3 (en) 2002-11-28
ATE524176T1 (de) 2011-09-15
CY1106581T1 (el) 2012-01-25
EP2298298A2 (en) 2011-03-23
IL179017A0 (en) 2007-03-08
DE69935249D1 (de) 2007-04-05
TR200200764T2 (tr) 2002-07-22
PT1140071E (pt) 2007-05-31
SI1588706T1 (sl) 2012-01-31
AU3043000A (en) 2000-07-31
BR9916576A (pt) 2001-10-02
CN1636561A (zh) 2005-07-13
EP1140071B1 (en) 2007-02-21
NO20100041L (no) 2001-08-16
HK1038888B (en) 2007-09-21
RU2008143545A (ru) 2010-05-10
AU2006203077A1 (en) 2006-08-10
AU2009220022A1 (en) 2009-10-15
TR200805741T2 (tr) 2008-10-21
DK1140071T3 (da) 2007-06-04
AU2003266433A1 (en) 2004-01-08
TR200805275T2 (tr) 2008-09-22
TR200805740T1 (tr) 2010-06-21
NZ511938A (en) 2004-02-27
DE69935249T2 (de) 2007-10-31
HUP0104780A2 (hu) 2002-04-29
JP5254258B2 (ja) 2013-08-07
RU2271809C2 (ru) 2006-03-20
IL179016A0 (en) 2007-03-08
CY1112395T1 (el) 2015-12-09
ES2373556T3 (es) 2012-02-06
SK9132001A3 (en) 2002-01-07
CZ297795B6 (cs) 2007-03-28
RU2361575C2 (ru) 2009-07-20
ID29856A (id) 2001-10-18
KR20010089681A (ko) 2001-10-08
PT1588706E (pt) 2011-12-21
PL349424A1 (en) 2002-07-29
EP1140071A1 (en) 2001-10-10
NZ587909A (en) 2012-05-25
CA2622805A1 (en) 2000-07-06
CN1331590A (zh) 2002-01-16
TR200101784T2 (tr) 2001-10-22
IL143233A (en) 2007-07-24
HK1038888A1 (en) 2002-04-04
RU2005124363A (ru) 2007-02-10
TR200605471T2 (tr) 2006-11-21
CZ20012306A3 (cs) 2001-12-12
CA2351357A1 (en) 2000-07-06
CA2622805C (en) 2011-05-10
SI1140071T1 (sl) 2007-08-31
PL199100B1 (pl) 2008-08-29
NO328775B1 (no) 2010-05-10
NO20013143L (no) 2001-08-16
NZ553010A (en) 2008-09-26
IL143233A0 (en) 2002-04-21
JP2002533390A (ja) 2002-10-08
CZ293257B6 (cs) 2004-03-17
DK1588706T3 (da) 2012-01-16
NO20013143D0 (no) 2001-06-22
EP1588706A2 (en) 2005-10-26
ES2281978T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
TR200605472T1 (tr) AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
BG66085B1 (bg) Фенилаланинови производни
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
DK1237584T3 (da) Receptorbindende konjugater
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
DE60126652D1 (de) Indolderivate
TR199800027T1 (tr) Difenilmetilen piperidin türevleri.
TR200000792T2 (tr) Vitronektin reseptör antagonistleri.
AP1402A (en) Prevention of migraine recurrence.
PT1146872E (pt) Utilizacao de antagonistas do receptor de angiotensina ii para tratamento de enfarte agudo do miocardio.
TR200103827T2 (tr) Farmakolojik kompleks
ES2189940T3 (es) Antagonista de receptor at1 para la estimulacion de la apoptosis.
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
MY131858A (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi